{{'Search' | translate}}
 

Potassium Chloride (KCl)

Company: Fisher ScientificTM
Catalog#: BP366-1
Bio-protocol()
Company-protocol()
Other protocol()

Expression and Purification of Recombinant Skd3 (Human ClpB) Protein and Tobacco Etch Virus (TEV) Protease from Escherichia coli
Author:
Date:
2020-12-05
[Abstract]  

Skd3 (encoded by human CLPB) is a mitochondrial AAA+ protein comprised of an N-terminal ankyrin-repeat domain and a C-terminal HCLR-clade nucleotide-binding domain. The function of Skd3 has long remained unknown due to challenges in purifying the protein to high quality and near homogeneity. Recently we described Skd3 as a human mitochondrial protein disaggregase that solubilizes proteins in the mitochondrial intermembrane space. This protocol overcomes the challenges associated with purifying Skd3 and allows for in depth in vitro study of Skd3 activity. Tobacco etch virus (TEV) protease is required in the purification of Skd3. Thus, we also describe how to purify high quality TEV protease for use in the purification of Skd3, other purification protocols, and in vitro assays requiring TEV

...
[摘要]  [摘要] Skd3(由人类CLPB编码)是一种线粒体AAA +蛋白,由N末端锚蛋白重复域和C末端HCLR分支核苷酸结合域组成。由于在纯化蛋白质达到高质量和接近均质性方面的挑战,Skd3的功能长期未知。最近,我们描述Skd3作为人类线粒体蛋白disaggregase ,在线粒体膜间间隙增溶蛋白。该协议克服了与纯化Skd3相关的挑战,并允许对Skd3活性进行深入的体外研究。Skd3的纯化需要烟草蚀刻病毒(TEV)蛋白酶。因此,我们还描述了如何净化高质量TEV蛋白酶可用于纯化Skd3,其他纯化方案以及需要TEV蛋白酶的体外测定。


[背景] Skd3是一种线粒体AAA +蛋白,与多系统线粒体疾病VII型3-甲基谷氨酸酸尿症(MGCA7)有关(Capo-Chichi等人,2015; Kanabus等人,2015; Saunders等人,, 2015; Wortmann等人,2015 ; Kiykim等人,2016 )。由于在体外研究Skd3的能力有限,因此对生物学功能和这些突变对Skd3活性的影响的研究仍难以捉摸(Cupo和Shorter,2020; ...

Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells
Author:
Date:
2020-07-05
[Abstract]  Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally ... [摘要]  [摘要] 多能干细胞(PSCs)有潜力提供同质的T细胞群体,这些细胞可以在临床规模上生长,并通过基因工程来满足特定的临床需求。OP9-DLL4是一种异位表达Notch配体Delta-like 4(DLL4)的基质细胞系,用于支持psc向T淋巴细胞的分化。本文概述了从人类和非人类灵长类(NHP)PSC中产生T细胞的几种方法,包括在OP9喂食者或特定条件下对PSC进行初始造血分化,然后将OP9-DLL4细胞与PSC衍生的造血祖细胞(HPs)共培养,从而有效地分化成T淋巴细胞。此外,我们描述了一个从有条件表达ETS1的hPSCs中产生健壮T细胞的方案。所提出的协议提供了一个平台,用于疾病建模和评估其在大型动物模型免疫治疗中的应用。

[背景] T淋巴细胞(T细胞)在细胞介导的免疫反应中起着关键作用,参与肿瘤细胞的监测和杀伤。在过去的几十年里,已经开发了几种策略来重定向、培养和/或增强抗肿瘤的T淋巴细胞(Houot等人,2015年;June等人,2018年),并将其用于基于T细胞的过继免疫治疗。最近的临床试验表明,用嵌合抗原受体(CAR)-T细胞治疗复发性和难治性淋巴瘤患者的疗效显著(Riviere和Sadelain,2017)。

人类多能干细胞(hPSCs),包括胚胎(hESCs)和诱导(hiPSCs),为生产用于过继性细胞免疫疗法的T细胞提供了一种很有前景的资源,可与基因工程技术相结合,产生现成的CAR ...

Comments